Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor-based therapy in refractory multiple myeloma
2024-511608-18-00Phase 2Authorised
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of selinexor, bortezomib and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall response rate. Planned start Jun 2020; status: authorised.
02
Drugs
selinexorbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511608-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511608-18-00.